David Bienvenue | Director of Protein Sciences
Aptevo Therapeutics

Appearances:

Day 2 Antibody Congress @ 12:01

ADAPTIR™ Bispecifics, a novel platform for development of immuno-oncology therapeutics

Plenary

• Key features and differentiating aspects of the ADAPTIR™ bispecific platform, including new preclinical in vivo and in vitro activity, pharmacokinetic and manufacturability data.  
• ADAPTIR™ bispecific proteins offer advantages over other formats, derived from the flexible and modular nature of the ADAPTIR™ structure. 
• Potent biological activity can be achieved, while retaining traditional antibody-like manufacturing characteristics. 
• One ADAPTIR™ molecule is currently undergoing clinical trials, with several more bispecific immunotherapies in preclinical development.

David Bienvenue, Director of Protein Sciences, Aptevo Therapeutics